ImmunityBio Doses First Patients In Phase 1 Clinical Study Of CAR-NK Cell Therapy For Relapsed B-Cell Non-Hodgkin Lymphoma
Portfolio Pulse from Benzinga Newsdesk
ImmunityBio has initiated a Phase 1 clinical study of its CAR-NK cell therapy for relapsed B-Cell Non-Hodgkin Lymphoma. This marks the company's first trial of CAR-NK cellular therapy in liquid tumors and the first natural killer cell-based therapy study in Africa. Full enrollment is expected by Q1 2025.
October 24, 2024 | 1:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ImmunityBio has dosed the first patients in its Phase 1 clinical study of CAR-NK cell therapy for relapsed B-Cell Non-Hodgkin Lymphoma. This is a significant step for the company as it is their first trial of this kind in liquid tumors and the first NK cell-based therapy study in Africa.
The initiation of a Phase 1 trial for a novel CAR-NK cell therapy represents a potential breakthrough in cancer treatment, which could positively impact ImmunityBio's stock. The trial's uniqueness as the first NK cell-based therapy study in Africa adds to its significance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90